PetCure Oncology reaches 10,000 radiation therapy patients

PetCure Oncology has reached 10,000 radiation therapy patients treated since opening in 2015, marking a notable benchmark for one of the most visible companies trying to expand access to advanced veterinary radiation oncology in private practice. In its January 7, 2026 announcement, the Austin-based organization said the milestone reflects a decade-long effort to make stereotactic radiation a more realistic referral option outside academic hospitals. (petcureoncology.com)

That framing matters because access has long been one of the limiting factors in veterinary radiation therapy. PetCure says that when it launched, stereotactic radiation was largely concentrated in academic settings and there were fewer than 70 traditional veterinary radiation therapy facilities in the U.S. The company’s earlier milestones help show the pace of adoption: it reported 8,000 pets treated in April 2024, after earlier public milestones at 3,000 and 4,000-plus patients in prior years. (petcureoncology.com)

The core clinical pitch has stayed consistent. PetCure’s stereotactic radiosurgery and stereotactic radiation therapy programs are designed to deliver highly targeted treatment in one to three sessions for selected cases, compared with roughly 15 to 20 or more fractions for conventional protocols. The company says that shorter treatment courses can reduce repeated anesthesia events and compress the treatment timeline for pet parents and referring practices. PetCure’s current materials also position the service as part of a broader Thrive Pet Healthcare specialty network, with referral tools, imaging review, and telehealth support intended to make consultation easier for primary care teams. (petcureoncology.com)

PetCure executives have explicitly tied the 10,000-patient mark to workforce and access constraints in the specialty. In a recent company Q&A, chief medical officer Neal Mauldin said there are only about 100 radiation oncologists in the world, and that expanding access to that limited expertise has been a central focus. That aligns with broader specialty scarcity signals elsewhere in the profession: a 2025 veterinary newsletter citing AVMA data said the U.S. had 129 radiation oncologists in 2021, while the Veterinary Cancer Society’s facility list shows a relatively small national footprint of hospitals offering radiation services, especially stereotactic capability. (petcureoncology.com)

Independent commentary on this specific milestone was limited, but the broader specialty conversation supports PetCure’s access argument while also pointing to the need for stronger evidence standards. A 2018 survey of stereotactic radiation therapy in veterinary medicine found users wanted clearer definitions, more transparency, and stronger multi-institutional research collaboration. More recently, a 2024 systematic review noted that increasing numbers of dogs and cats are being treated with stereotactic techniques, but also highlighted reporting gaps in the literature. In other words, access has improved, but the field is still working toward more standardized evidence and outcome reporting. (pmc.ncbi.nlm.nih.gov)

Why it matters: For veterinarians, this is a practical referral story as much as an industry milestone. More radiation capacity in private specialty settings can change conversations around brain tumors, nasal tumors, soft tissue sarcomas, incompletely excised tumors, palliative cases, and other patients for whom geography or treatment burden once made referral unrealistic. Shorter-course radiation may also be easier for some pet parents to accept, particularly when repeated anesthesia, travel, and time away from work are barriers. At the same time, the growth in access raises familiar clinical questions: which cases are best suited to stereotactic protocols, how outcomes compare across centers and indications, and how practices should counsel pet parents on cost, goals of care, and expected toxicities. (petcureoncology.com)

There’s also a competitive and technology angle. In November 2025, Empyrean Medical Systems announced a partnership with Thrive Pet Healthcare to place its Sirius advanced radiation platform at PetCure Oncology’s Seattle site, signaling continued investment in newer delivery systems and image-guided precision workflows. If those rollouts are paired with peer-reviewed outcomes, they could further shape how community veterinarians think about referral thresholds and what “advanced” radiation oncology looks like in private practice. (empyreanmed.com)

What to watch: The next meaningful signal will be whether PetCure follows this milestone with peer-reviewed clinical outcomes, additional center expansion, or new data showing where shorter-course radiation is delivering the clearest benefit in real-world veterinary practice. (petcureoncology.com)